Arnonk Karni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5088986/publications.pdf

Version: 2024-02-01

61	3,177	304368	155451
papers	citations	22 h-index	55 g-index

61	61	61	4329
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Susacâ€™s syndrome â€“ A new ocular finding and disease outcome. Eye, 2022, 36, 781-788.	1.1	2
2	Frailty and Falls in People Living With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2022, 103, 952-957.	0.5	6
3	Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study. Scientific Reports, 2022, 12, 4555.	1.6	1
4	The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 474.	1.8	2
5	Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Frontiers in Immunology, 2022, 13, 868915.	2.2	32
6	Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation. International Journal of Molecular Sciences, 2021, 22, 2182.	1.8	4
7	Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders. Neurotherapeutics, 2021, 18, 1798-1814.	2.1	5
8	High Î² free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	5
9	Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials. Journal of Vestibular Research: Equilibrium and Orientation, 2020, , 1-7.	0.8	0
10	A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity. Journal of Neurology, 2020, 267, 1912-1921.	1.8	46
11	Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials. Journal of Vestibular Research: Equilibrium and Orientation, 2020, 30, 393-399.	0.8	2
12	Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis. CNS Drugs, 2019, 33, 1229-1237.	2.7	6
13	Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure. Journal of Neuroimmunology, 2019, 327, 36-40.	1.1	3
14	Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder. Neurology: Clinical Practice, 2019, 9, 524-526.	0.8	4
15	Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 260-263.	1.1	17
16	A tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences. International Journal of Neuroscience, 2019, 129, 313-319.	0.8	7
17	Intractable vomiting and the medulla: neuromyelitis optica spectrum disorder presenting as area postrema syndrome. Postgraduate Medical Journal, 2018, 94, 724-724.	0.9	1
18	Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. Journal of Neuroimmunology, 2017, 307, 47-52.	1.1	4

#	Article	IF	Citations
19	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	13.9	1,324
20	Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis. Clinical Immunology, 2017, 183, 316-324.	1.4	6
21	High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2017, 310, 120-128.	1.1	14
22	Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation. Frontiers in Immunology, 2017, 8, 1432.	2.2	10
23	Characterization of patients with ocular myasthenia gravis â€" A case series. ENeurologicalSci, 2016, 4, 30-33.	0.5	11
24	Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms. Journal of Neuroimmunology, 2016, 298, 58-62.	1.1	5
25	Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-Î². Journal of Neuroimmunology, 2016, 292, 93-96.	1.1	3
26	Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. Journal of Neuroimmunology, 2016, 293, 65-70.	1.1	28
27	Teaching Neuro Images : Hypertrophic olivary degeneration in a young man with POLG gene mutation. Neurology, 2015, 84, e59.	1.5	7
28	Increased neutralization capacity of TNF-Î± in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-Î± receptors or anti-TNF-Î± autoantibody levels. Journal of Neuroimmunology, 2015, 286, 83-85.	1.1	6
29	Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients. Journal of Neuroimmunology, 2015, 278, 85-89.	1.1	7
30	Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse?. Multiple Sclerosis Journal, 2015, 21, 572-579.	1.4	29
31	Treatment with Anti-EGF Ab Ameliorates Experimental Autoimmune EncephalomyelitisviaInduction of Neurogenesis and Oligodendrogenesis. Multiple Sclerosis International, 2014, 2014, 1-9.	0.4	11
32	Central Nervous System Manifestation of IgG4-Related Disease. JAMA Neurology, 2014, 71, 767.	4.5	51
33	Multiple sclerosis is associated with psoriasis. A caseâ€"control study. Journal of the Neurological Sciences, 2014, 338, 226-228.	0.3	20
34	Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsingâ€"remitting multiple sclerosis. Journal of Neuroimmunology, 2013, 264, 91-99.	1.1	20
35	Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis. Neurotherapeutics, 2013, 10, 77-88.	2.1	36
36	High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2013, 257, 82-89.	1.1	5

#	Article	IF	Citations
37	Seasonal and H1N1v influenza vaccines in MS: Safety and compliance. Journal of the Neurological Sciences, 2012, 314, 102-103.	0.3	21
38	Leukoaraiosis is associated with arterial wall thickness: A quantitative analysis. Neuropathology, 2012, 32, 227-233.	0.7	8
39	Reduced ErbB4 Expression in Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis. Multiple Sclerosis International, 2011, 2011, 1-7.	0.4	13
40	Reduced production of noggin by immune cells of patients with relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2011, 232, 171-178.	1.1	18
41	Low and dysregulated production of follistatin in immune cells of relapsingâ€“remitting multiple sclerosis patients. Journal of Neuroimmunology, 2011, 238, 96-103.	1.1	15
42	Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle and Nerve, 2011, 43, 893-894.	1.0	23
43	Nightly Sublingual Tizanidine HCl in Multiple Sclerosis. Clinical Neuropharmacology, 2010, 33, 151-154.	0.2	15
44	Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis. Journal of the Neurological Sciences, 2010, 295, 31-37.	0.3	17
45	The place of the botulinum toxin in the management of multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 592-596.	0.6	27
46	Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?. Archives of Neurology, 2009, 66, 538.	4.9	11
47	Interferon-Î² therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. Journal of Neuroimmunology, 2009, 211, 114-119.	1.1	38
48	Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. Journal of Neuroimmunology, 2008, 195, 186-193.	1.1	106
49	In vitro induction of regulatory T cells by anti-CD3 antibody in humans. Journal of Autoimmunity, 2008, 30, 21-28.	3.0	45
50	Serum anti-Glc(Î±1,4)Glc(Î±) antibodies as a biomarker for relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2006, 244, 59-68.	0.3	58
51	Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. Journal of Immunology, 2006, 177, 4196-4202.	0.4	148
52	Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. Journal of Neuroimmunology, 2005, 163, 157-164.	1.1	71
53	Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. Journal of Neuroimmunology, 2005, 167, 215-218.	1.1	165
54	Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-Î³ production of CD8+ T cells in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2004, 146, 189-198.	1.1	45

#	Article	IF	Citations
55	PD-1 ligands, negative regulators for activation of naÃ¯ve, memory, and recently activated human CD4+ T cells. Cellular Immunology, 2004, 230, 89-98.	1.4	64
56	The Frequency of Multiple Sclerosis in Jewish and Arab Populations in Greater Jerusalem. Neuroepidemiology, 2003, 22, 82-86.	1.1	37
57	Increased T cell reactivity to amyloid Î² protein in older humans and patients with Alzheimer disease. Journal of Clinical Investigation, 2003, 112, 415-422.	3.9	173
58	IL-18 is linked to raised IFN-Î³ in multiple sclerosis and is induced by activated CD4+ T cells via CD40â€“CD40 ligand interactions. Journal of Neuroimmunology, 2002, 125, 134-140.	1.1	82
59	HLA Class II Susceptibility to Multiple Sclerosis Among Ashkenazi and Non-Ashkenazi Jews. Archives of Neurology, 1999, 56, 555.	4.9	70
60	Elevated Levels of Antibody to Myelin Oligodendrocyte Glycoprotein Is Not Specific for Patients With Multiple Sclerosis. Archives of Neurology, 1999, 56, 311.	4.9	94
61	Association of MS with thyroid disorders. Neurology, 1999, 53, 883-883.	1.5	73